Mumbai, Feb. 18 -- YESINTEK is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease.

In December last year, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion on YESINTEK and had recommended approval of the same.

Biocon Biologics (BBL) is a fully integrated global biosimilars company and the subsidiary of Biocon.

Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several ...